Droxidopa capsules + Placebo capsules
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Symptomatic Neurogenic Orthostatic Hypotension
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Trial Timeline
Feb 11, 2016 → Sep 9, 2022
NCT ID
NCT02586623About Droxidopa capsules + Placebo capsules
Droxidopa capsules + Placebo capsules is a approved stage product being developed by Lundbeck for Symptomatic Neurogenic Orthostatic Hypotension. The current trial status is completed. This product is registered under clinical trial identifier NCT02586623. Target conditions include Symptomatic Neurogenic Orthostatic Hypotension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02586623 | Approved | Completed |
Competing Products
20 competing products in Symptomatic Neurogenic Orthostatic Hypotension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |